Latest News about CRSP
Recent news which mentions CRSP
Why CRISPR Therapeutics Stock Charged Northward This Week
November 03, 2023
Tickers
CRSP
From Motley Fool
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
November 03, 2023
From Motley Fool
3 Healthcare Stocks to Buy Hand Over Fist in November
November 03, 2023
From Motley Fool
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
November 02, 2023
From Motley Fool
Crispr Therapeutics’ stock soars as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved
November 01, 2023
From MarketWatch
Why Are Stocks Up Today?
November 01, 2023
From InvestorPlace
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
November 01, 2023
From InvestorPlace
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
November 01, 2023
Tickers
CRSP
From InvestorPlace
AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today
October 31, 2023
From Benzinga
CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision
October 31, 2023
Tickers
CRSP
From InvestorPlace
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
From Motley Fool
From InvestorPlace
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
October 27, 2023
From Benzinga
Vertex Pharmaceuticals: Buy at the High?
October 26, 2023
From Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
October 26, 2023
From Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
October 25, 2023
From Motley Fool
3 No-Brainer Stocks to Buy Right Now for Less than $100
October 23, 2023
From Motley Fool
7 Biotech Stocks to Get In Now Before Investors Catch On
October 23, 2023
From InvestorPlace
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
October 21, 2023
From Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
From InvestorPlace
From Benzinga
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
October 17, 2023
From Benzinga
From Benzinga
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
October 17, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
From Benzinga
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
October 16, 2023
From Motley Fool
From Motley Fool
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.